Role of interleukin-23/interleukin-17 axis in T-cell-mediated actions in hypertension

Current knowledge suggests that hypertension is in part mediated by immune mechanisms. Both interleukin (IL)-23 and IL-17 are up-regulated in several experimental hypertensive rodent models, as well as in hypertensive humans in observational studies. Recent preclinical studies have shown that either IL-23 or IL-17A treatment induce blood pressure elevation. However, the IL-23/IL-17 axis has not been a major therapeutic target in hypertension, unlike in other autoimmune diseases. In this review, we summarize current knowledge on the role of these cytokines in immune mechanisms contributing to hypertension, and discuss the potential of IL-23/IL-17-targeted therapy for treatment of hypertension. [GRAPHICS] .

Automated summary

Hypertension is partially mediated by immune mechanisms, with IL-23 and IL-17 playing important roles. The IL-23/IL-17 axis has not been a major therapeutic target for hypertension treatment, but shows potential for targeting therapy.